Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 5, 2022
We are revolutionizing cancer treatment by activating
the untapped power of the innate immune system to eradicate tumors. Our novel and proprietary technology binds NK cells and other innate immune cells directly to tumor cells, allowing for tumor destruction.
This approach is versatile and scalable.
Our approach is differentiated and IP-protected, and has the promise to help patients who
have already undergone earlier lines of therapy that proved to be unsuccessful.
We have entered select partnerships with esteemed pharmaceutical companies who share our passion for bringing change to the treatment of cancer.
We trust that we can help those who have been
left behind due to a lack of efficacy or unpredictable
toxicity with traditional therapies. Clinical results already
light the way for patients suffering from multiple types of
cancer. Initial reported data have demonstrated unprecedented ORR in patients who had undergone
earlier lines of therapy that proved to be unsuccessful—including one patient who was about to enter hospice care.
IP=intellectual property; NK=natural killer; ORR=objective response rate.